How M.D. was paid
$4.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Sanjiv K. Patel, M.D.President and Chief Executive Officer | $707,846 | $3,513,900 | $424,708 | — | $4,646,454 | $4,646,454 |
| Thomas CatinazzoChief Financial Officer | $486,100 | $874,500 | $194,440 | $13,573 | $1,568,613 | $1,568,613 |
| Donald Bergstrom, M.D., Ph.D.President, Research & Development | $554,250 | $1,272,000 | $249,413 | $14,000 | $2,089,663 | $2,089,663 |
| Peter RahmerChief Corporate Development Officer | $469,050 | $874,500 | $187,620 | $14,000 | $1,545,170 | $1,545,170 |
| Brian AdamsFormer Chief Legal Officer | $291,182 | $874,500 | — | $11,647 | $1,177,329 | $1,177,329 |
What changed and why
- $4.6MSanjiv K. Patel earned total compensation of $4,646,454 in fiscal 2025.
- 100%The board determined the company achieved 100% of its corporate goals for 2025.
- The company initiated a global Phase 3 registrational study for zovegalisib plus fulvestrant.
- Mr. Adams resigned from his position as Chief Legal Officer effective August 8, 2025.
- 56%Approximately 56% of stockholders voted in favor of the say-on-pay proposal in 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.